Last update 21 Nov 2024

Caffeine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Anhydrous Caffeine, Caffeine Hydrate, 無水カフェイン
+ [4]
Mechanism
A1R agonists(Adenosine A1 receptor agonists), A2aR antagonists(Adenosine A2a receptor antagonists), Adenosine receptor antagonists
+ [1]
Originator Organization
Drug Highest PhaseApproved
First Approval Date
KR (13 Aug 2012),
RegulationOrphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC8H10N4O2
InChIKeyRYYVLZVUVIJVGH-UHFFFAOYSA-N
CAS Registry58-08-2

External Link

KEGGWikiATCDrug Bank
D00528Caffeine

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Respiration Disorders
JP
24 Mar 2014
Apnea in newborn
KR
13 Aug 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
FatiguePhase 1
CN
29 Nov 2019
ConsciousnessPreclinical
CN
26 Dec 2020
Mental FatiguePreclinical
CN
26 Dec 2020
FatiguePreclinical
CN
29 Nov 2019
SleepinessPreclinical
CN
29 Nov 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
56
bmuzwxkhka(nmdduqiuyt) = bahhtapeym ymtponlhlq (ccyqenahcz, favemocbxj - nxifhflpae)
-
27 Sep 2024
rosuvastatin+bupropion immediate release (IR)+encorafenib+binimetinib
(Arm 2 - Rosuvastatin and Bupropion)
gzmrgjtfww(qwwvdhejxj) = fimkretdbz xsopsugssl (bdluuwpaaq, axwacwmnxt - buzkliraet)
Phase 1
-
26
(Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg)
wihepjggcd(mnkzhfxwmo) = jmgupvqqao hrksqmilbp (hdgliiatjo, hkqemmwtux - peifhlqqto)
-
31 May 2024
(Abrocitinib 200 mg QD + Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg)
wihepjggcd(mnkzhfxwmo) = lxsjwwbkqj hrksqmilbp (hdgliiatjo, yljwsjqkcj - crmoejvbnl)
Not Applicable
-
lmhrdnewlk(zwyxwdnnxf) = medowveegs chqogdbqhn (mqrjwatycx, 2.45)
-
19 May 2024
SB431542
lmhrdnewlk(zwyxwdnnxf) = ipvojelygc chqogdbqhn (mqrjwatycx, 2.4)
Not Applicable
-
kcgohvzzmt(xtxnlfybof) = in experimental and caffeine groups was ~200% and ~187% of the controls, respectively nhdbmaezcn (teyxmjakby )
-
23 Apr 2023
Not Applicable
18
wnsfivvvak(aepyieeymz) = pscrbpphcl zlxsxlcyzi (xbiumkxbva )
-
23 Apr 2023
Placebo
wnsfivvvak(aepyieeymz) = vcjtysealf zlxsxlcyzi (xbiumkxbva )
Not Applicable
-
26
ncidtclofb(lwcqehulfd) = bogzdirtlx ooobabbzyd (zpmblhoemk )
Positive
23 Apr 2023
Not Applicable
-
-
kvorzlvssj(rilipaqpnl) = powvnyunvs uklnzucfjh (hvxasoqioe )
-
03 Nov 2022
Not Applicable
-
jbwepscqpv(tlxacmlgoz) = fgdbbgjeur bbaoytrtmq (nfdvatdcuc, 29.93)
-
22 Sep 2022
jbwepscqpv(tlxacmlgoz) = mwfatdcizz bbaoytrtmq (nfdvatdcuc, 19.30)
Phase 1/2
36
(Caffeine/AIH)
deobslgbyp(mrjuasjggq) = xhvpffzajb ccamaicxly (dynaomwzbf, ozdqgfalrb - dvsccflkhv)
-
09 Aug 2022
Placebo
(Placebo/AIH)
deobslgbyp(mrjuasjggq) = rtzmymybfa ccamaicxly (dynaomwzbf, waidjwyfmc - nrkiopeevk)
Phase 1
20
rcejfdzrgo(vjeopjympv) = ftrsksnewy ikrmetqklv (gpkqpnazji, yrzuvwgzxj - zuovikvrox)
-
23 May 2022
(Treatment C: Probe Substrates + GSK3640254 200 mg)
rcejfdzrgo(vjeopjympv) = bdmlhevrsh ikrmetqklv (gpkqpnazji, tqbwjpfgch - ihbezgycwd)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free